Zacks Research Has Positive Outlook for RDY Q4 Earnings

Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) - Analysts at Zacks Research raised their Q4 2026 earnings per share estimates for Dr. Reddy's Laboratories in a report released on Monday, March 17th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.20 for the quarter, up from their previous estimate of $0.19. The consensus estimate for Dr. Reddy's Laboratories' current full-year earnings is $0.80 per share.

Several other research firms also recently weighed in on RDY. StockNews.com downgraded Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, December 6th. Nomura cut Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research report on Thursday, December 19th.

Dr. Reddy's Laboratories Stock Performance

Shares of Dr. Reddy's Laboratories stock traded up $0.01 on Thursday, hitting $13.72. 3,085,934 shares of the company's stock were exchanged, compared to its average volume of 1,270,219. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The stock has a market capitalization of $11.45 billion, a PE ratio of 21.84 and a beta of 0.48. Dr. Reddy's Laboratories has a 1 year low of $12.50 and a 1 year high of $16.89. The company has a 50-day simple moving average of $13.63 and a 200-day simple moving average of $14.67.

Remove Ads

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%.

Institutional Trading of Dr. Reddy's Laboratories

Several institutional investors and hedge funds have recently modified their holdings of RDY. Wellington Management Group LLP increased its stake in Dr. Reddy's Laboratories by 431.8% in the 4th quarter. Wellington Management Group LLP now owns 896,165 shares of the company's stock worth $14,150,000 after buying an additional 727,665 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in shares of Dr. Reddy's Laboratories in the fourth quarter worth about $206,000. NorthCrest Asset Manangement LLC grew its position in shares of Dr. Reddy's Laboratories by 395.9% during the fourth quarter. NorthCrest Asset Manangement LLC now owns 55,025 shares of the company's stock worth $869,000 after purchasing an additional 43,930 shares in the last quarter. Pinnacle Wealth Planning Services Inc. raised its stake in Dr. Reddy's Laboratories by 203.4% during the 4th quarter. Pinnacle Wealth Planning Services Inc. now owns 26,744 shares of the company's stock valued at $422,000 after purchasing an additional 17,930 shares during the period. Finally, B. Riley Wealth Advisors Inc. lifted its holdings in Dr. Reddy's Laboratories by 829.5% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 57,350 shares of the company's stock worth $906,000 after purchasing an additional 51,180 shares in the last quarter. 3.85% of the stock is currently owned by institutional investors.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.